Scarica l'app Stockscreener
4.56
0.00%
0.00
Dopo l'orario di chiusura:
4.52
-0.04
-0.88%
Precedente Chiudi:
$4.56
Aprire:
$4.37
Volume 24 ore:
4.72M
Relative Volume:
0.76
Capitalizzazione di mercato:
$985.77M
Reddito:
$76.20M
Utile/perdita netta:
$-17.37M
Rapporto P/E:
501.10
EPS:
0.0091
Flusso di cassa netto:
$-75.81M
1 W Prestazione:
+3.17%
1M Prestazione:
-14.61%
6M Prestazione:
+39.02%
1 anno Prestazione:
+649.14%
Intervallo 1D:
$4.29
$4.575
Intervallo di 1 settimana:
$4.25
$4.8699
Portata 52W:
$0.40
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.56 | 985.77M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CTMX Technical Analysis & ETF Price Forecast - Intellectia AI
CytomX Therapeutics (CTMX) price target increased by 47.30% to 13.90 - MSN
CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN
CytomX Therapeutics, Inc. (CTMX) latest stock news and headlines - Yahoo Finance Singapore
CTMX Technical Analysis & Stock Price Forecast - Intellectia AI
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
CytomX Therapeutics Signals Progress in Varseta-M Trial - TipRanks
Aug Update: Does CytomX Therapeutics Inc have strong EBITDA marginsTreasury Yields & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
US Market Wrap: Is CytomX Therapeutics Inc a good stock for dollar cost averaging2026 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
CytomX Therapeutics launches $250M public offering - MSN
CytomX Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Aug Fed Impact: What hedge funds are buying CytomX Therapeutics Inc2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
CTMX stock rallies on strong phase I colorectal cancer study data - MSN
Performance Recap: Is CytomX Therapeutics Inc stock showing strong momentum2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress - Insider Monkey
CytomX Therapeutics (NASDAQ:CTMX) Trading 4.9% HigherShould You Buy? - MarketBeat
Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Vanguard (CTMX) reports 0 shares; disaggregation after internal realignment - Stock Titan
How The CytomX Therapeutics (CTMX) Narrative Is Shifting With New Colorectal Cancer Data - Yahoo Finance
Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026 - Meyka
Barclays Maintains CytomX Therapeutics (CTMX) Overweight Recommendation - MSN
Jefferies raises CytomX Therapeutics (CTMX) price target to $16 - msn.com
CytomX highlights clinical progress for lead cancer drug in Q4 update - MSN
Jefferies reiterates Buy rating on CytomX stock after phase 1 data - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler - MarketBeat
CTMX: Piper Sandler Raises Price Target to $12 | CTMX Stock News - gurufocus.com
Piper Sandler raises CytomX stock price target on drug trial data - Investing.com Canada
CytomX Therapeutics (CTMX) reports Q4 loss, misses revenue estimates - MSN
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data - AOL.com
How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - Sahm
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results - Yahoo Finance
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Insider Monkey
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing - marketscreener.com
Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean McCarthy, CytomX Therapeutics CEO, sells $764k in stock By Investing.com - Investing.com Canada
CytomX therapeutics (CTMX) chief medical officer sells $136k in stock - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock By Investing.com - Investing.com Australia
Ogden, CytomX Therapeutics CFO, sells $124k in shares By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):